Literature DB >> 3304385

Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers.

S Looareesuwan, N J White, D A Warrell, I Forgo, U G Dubach, U B Ranalder, D E Schwartz.   

Abstract

1 A mefloquine hydrochloride tablet (250 mg base equivalent to 4.8 +/- 0.6 mg kg-1; mean +/- s.d.) and deuterium labelled mefloquine hydrochloride solution (250 mg base) were given to six adult male Thai patients with acute falciparum malaria and six healthy Swiss adult male volunteers (equivalent to 3.5 +/- 0.1 mg kg-1). 2 The relative bioavailability of the tablet formulation derived from comparison of the areas under the plasma concentration-time curves was similar in both groups; 87 +/- 11% and 89 +/- 10% (mean +/- s.d.). 3 The rate of drug absorption appeared to be similar in the two groups but peak plasma mefloquine concentrations were approximately three times higher in the Thai patients (1004 +/- 276 ng ml-1 for the tablet and 1085 +/- 280 ng ml-1 for the suspension) compared with the Swiss volunteers (319 +/- 73 ng ml-1 for the tablet, and 369 +/- 121 ng ml-1 for the suspension). 4 Estimates of the oral clearance CLpo of unlabelled mefloquine were significantly lower (17.5 +/- 4.4 ml h-1 kg-1) in the Thai patients compared with 28.8 +/- 3.5 ml h-1 kg-1 in the Swiss volunteers; P less than 0.05). Terminal elimination half-lives were significantly shorter in the patients (10.3 +/- 2.5 days) than in the volunteers (16.7 +/- 1.9 days; P less than 0.005). Differences of a similar magnitude were observed when comparing the pharmacokinetic parameters derived from the deuteromefloquine plasma concentrations. 5 Both genetic and disease related factors are likely to account for the large pharmacokinetic differences between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304385      PMCID: PMC1386277          DOI: 10.1111/j.1365-2125.1987.tb03133.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Kinetics of a new antimalarial, mefloquine.

Authors:  R E Desjardins; C L Pamplin; J von Bredow; K G Barry; C J Canfield
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 2.  Drug metabolism by intestinal microorganisms.

Authors:  R R Scheline
Journal:  J Pharm Sci       Date:  1968-12       Impact factor: 3.534

3.  Binding of quinine to plasma proteins in falciparum malaria.

Authors:  K Silamut; N J White; S Looareesuwan; D A Warrell
Journal:  Am J Trop Med Hyg       Date:  1985-07       Impact factor: 2.345

4.  Mefloquine (WR 142,490) in the treatment of human malaria.

Authors:  C M Trenholme; R L Williams; R E Desjardins; H Frischer; P E Carson; K H Rieckmann; C J Canfield
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

5.  Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites.

Authors:  D E Schwartz; G Eckert; D Hartmann; B Weber; D Richard-Lenoble; J M Ekue; M Gentilini
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

6.  Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090.

Authors:  J Y Mu; Z H Israili; P G Dayton
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

Review 7.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

8.  Highly sensitive and specific determination of mefloquine in biological fluids using gas chromatography mass spectrometry with selected ion monitoring.

Authors:  D E Schwartz; U B Ranalder
Journal:  Biomed Mass Spectrom       Date:  1981-12

9.  Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria.

Authors:  P Chanthavanich; S Looareesuwan; N J White; D A Warrell; M J Warrell; J H DiGiovanni; J von Bredow
Journal:  Am J Trop Med Hyg       Date:  1985-11       Impact factor: 2.345

10.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; D Bunnag; T Harinasuta
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

View more
  27 in total

Review 1.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Effect of ampicillin on mefloquine pharmacokinetics in Thai males.

Authors:  J Karbwang; K Na Bangchang; D J Back; D Bunnag
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Divided-dose kinetics of mefloquine in man.

Authors:  G Franssen; B Rouveix; J Lebras; J Bauchet; F Verdier; C Michon; F Bricaire
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

4.  A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.

Authors:  Trevor N Johnson; Yumi Cleary; Neil Parrott; Bruno Reigner; James R Smith; Stephen Toovey
Journal:  Br J Clin Pharmacol       Date:  2018-11-05       Impact factor: 4.335

6.  Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Authors:  B G Charles; A Blomgren; P E Nasveld; S J Kitchener; A Jensen; R M Gregory; B Robertson; I E Harris; M P Reid; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  2007-01-11       Impact factor: 2.953

Review 7.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  A small amount of fat does not affect piperaquine exposure in patients with malaria.

Authors:  Anna Annerberg; Khin Maung Lwin; Niklas Lindegardh; Sakchai Khrutsawadchai; Elizabeth Ashley; Nicholas P J Day; Pratap Singhasivanon; Joel Tarning; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

9.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 10.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.